Outcomes of eyes with lesions composed of >50% blood in the comparison of age-related macular degeneration treatments trials (CATT)

Ophthalmology

Volumn 122, Issue 2, 2015, Pages 391-398.e5

  Altaweel, Michael M ^a   Daniel, Ebenezer ^b   Martin, Daniel F ^c   Mittra, Robert A ^d   Grunwald, Juan E ^b   Lai, Michael M ^e   Melamud, Alexander ^e   Morse, Lawrence S ^f   Huang, Jiayan ^b   Ferris, Frederick L ^g   Fine, Stuart L ^h   Maguire, Maureen G ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d VitreoRetinal Surgery   (United States)

^e Retina Group of Washington   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g NATIONAL EYE INSTITUTE   (United States)

^h UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; BLOOD; COHORT ANALYSIS; COLOR FUNDUS PHOTOGRAPHY; CONTROLLED STUDY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PHOTOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINAL THICKNESS; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CHOROIDAL NEOVASCULARIZATION; CLINICAL TRIAL; COMPARATIVE STUDY; INTRAVITREAL DRUG ADMINISTRATION; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINAL HEMORRHAGE; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BEVACIZUMAB; CHOROIDAL NEOVASCULARIZATION; COHORT STUDIES; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; PROSPECTIVE STUDIES; RANIBIZUMAB; RETINAL HEMORRHAGE; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84921613040     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2014.08.020     Document Type: Article

References (39)

1. S.R. Bennett, J.C. Folk, C.F. Blodi, and M. Klugman Factors prognostic of visual outcome in patients with subretinal hemorrhage Am J Ophthalmol 109 1990 33 37
2. R.L. Avery, S. Fekrat, B.S. Hawkins, and N.M. Bressler Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration Retina 16 1996 183 189
3. A. Scupola, G. Coscas, G. Soubrane, and E. Balestrazzi Natural history of macular subretinal hemorrhage in age-related macular degeneration Ophthalmologica 213 1999 97 102
4. Submacular Surgery Trials (SST) Research Group Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings. SST report no. 13 Ophthalmology 111 2004 1993 2006
5. T. Mizutani, T. Yasukawa, and Y. Ito Pneumatic displacement of submacular hemorrhage with or without tissue plasminogen activator Graefes Arch Clin Exp Ophthalmol 249 2011 1153 1157
6. C.Y. Chen, C. Hooper, and D. Chiu Management of submacular hemorrhage with intravitreal injection of tissue plasminogen activator and expansile gas Retina 27 2007 321 328
7. B.A. Handwerger, B.A. Blodi, and S.R. Chandra Treatment of submacular hemorrhage with low-dose intravitreal tissue plasminogen activator injection and pneumatic displacement Arch Ophthalmol 119 2001 28 32
8. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report 1 Arch Ophthalmol 117 1999 1329 1345
9. E.S. Gragoudas, A.P. Adamis, E.T. Cunningham Jr. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group Pegaptanib for neovascular age-related macular degeneration N Engl J Med 351 2004 2805 2816
10. P.J. Rosenfeld, D.M. Brown, J.S. Heier MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
11. D.M. Brown, P.K. Kaiser, M. Michels ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444
12. J.S. Heier, D.M. Brown, V. Chong VIEW 1 and VIEW 2 Study Groups Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration Ophthalmology 119 2012 2537 2548
13. M.A. Chang, D.V. Do, and S.B. Bressler Prospective one-year study of ranibizumab for predominantly hemorrhagic choroidal neovascular lesions in age-related macular degeneration Retina 30 2010 1171 1176
14. G. Shienbaum, C.A. Garcia Filho, and H.W. Flynn Jr. Management of submacular hemorrhage secondary to neovascular age-related macular degeneration with anti-vascular endothelial growth factor monotherapy Am J Ophthalmol 155 2013 1009 1013
15. E. Stifter, S. Michels, and F. Prager Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage Am J Ophthalmol 144 2007 886 892
16. P. Iacono, M.B. Parodi, and U. Introini Intravitreal ranibizumab for choroidal neovascularization with large submacular hemorrhage in age-related macular degeneration Retina 34 2014 281 287
17. J.H. Kim, Y.S. Chang, and J.W. Kim Intravitreal anti-vascular endothelial growth factor for submacular hemorrhage from choroidal neovascularization Ophthalmology 121 2014 926 935
18. CATT Research Group Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 2011 1897 1908
19. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group D.F. Martin, M.G. Maguire, and S.L. Fine Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 2012 1388 1398
20. J.E. Grunwald, E. Daniel, and G.S. Ying CATT Research Group. Photographic assessment of baseline fundus morphologic features in the Comparison of Age-related Macular Degeneration Treatments Trials Ophthalmology 119 2012 1634 1641
21. F.C. DeCroos, C.A. Toth, S.S. Stinnett CATT Research Group Optical coherence tomography grading reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials Ophthalmology 119 2012 2549 2557
22. G.S. Ying, J. Huang, M.G. Maguire Comparison of Age-related Macular Degeneration Treatments Trials Research Group Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration Ophthalmology 120 2013 122 129
23. H. Glatt, and R. Machemer Experimental subretinal hemorrhage in rabbits Am J Ophthalmol 94 1982 762 773
24. C.A. Toth, L.S. Morse, and L.M. Hjelmeland Fibrin directs early retinal damage after experimental subretinal hemorrhage Arch Ophthalmol 109 1991 723 729
25. R.B. Bhisitkul, B.J. Winn, and O.T. Lee Neuroprotective effect of intravitreal triamcinolone acetonide against photoreceptor apoptosis in a rabbit model of subretinal hemorrhage Invest Ophthalmol Vis Sci 49 2008 4071 4077
26. L. Arias, and J. Monés Transconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the management of predominantly hemorrhagic age-related macular degeneration Clin Ophthalmol 4 2010 67 72
27. A.R. Skaf, and T. Mahmoud Surgical treatment of age-related macular degeneration Semin Ophthalmol 26 2011 181 191
28. W.J. Mayer, I. Hakim, and C. Haritoglou Efficacy and safety of recombinant tissue plasminogen activator and gas versus bevacizumab and gas for subretinal haemorrhage Acta Ophthalmol 91 2013 274 278
29. F. Treumer, J. Roider, and J. Hillenkamp Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage Br J Ophthalmol 96 2012 708 713
30. C. Kuhli-Hattenbach, I.B. Fischer, R. Schalnus, and L.O. Hattenbach Subretinal hemorrhages associated with age-related macular degeneration in patients receiving anticoagulation or antiplatelet therapy Am J Ophthalmol 149 2010 316 321
31. M.A. Tilanus, W. Vaandrager, and M.H. Cuypers Relationship between anticoagulant medication and massive intraocular hemorrhage in age-related macular degeneration Graefes Arch Clin Exp Ophthalmol 238 2000 482 485
32. J.C. Hwang, L.V. Del Priore, and K.B. Freund Development of subretinal fibrosis after anti-VEGF treatment in neovascular age-related macular degeneration Ophthalmic Surg Lasers Imaging 42 2011 6 11
33. N. Varshney, A. Jain, and V. Chan Anti-VEGF response in macular hemorrhage and incidence of retinal pigment epithelial tears Can J Ophthalmol 48 2013 210 215
34. C.K. Chan, C.H. Meyer, and J.G. Gross Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration Retina 27 2007 541 551
35. C.K. Chan, P. Abraham, and C.H. Meyer Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections Retina 30 2010 203 211
36. P.E. Carvounis, A.C. Kopel, and M.S. Benz Retinal pigment epithelium tears following ranibizumab for exudative age-related macular degeneration Am J Ophthalmol 143 2007 504 505
37. E.T. Cunningham Jr., L. Feiner, and C. Chung Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration Ophthalmology 118 2011 2447 2452
38. D. Sarraf, C. Chan, E. Rahimy, and P. Abraham Prospective evaluation of the incidence and risk factors for the development of RPE tears after high- and low-dose ranibizumab therapy Retina 33 2013 1551 1557
39. B. Todorich, I.U. Scott, H.W. Flynn Jr., and M.W. Johnson Evolving strategies in the management of submacular hemorrhage associated with choroidal neovascularization in the anti-vascular endothelial growth factor era Retina 31 2011 1749 1752